Drugs / RFASE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02237638 | Apr 2014 → Jan 2020 | metastatic malignant neoplasm | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RFASE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02237638 ↗ |
| Modality | Other / unclassified | “belongs to the adjuvant group of sulpholipopolysaccharides” NCT02237638 ↗ |
| Route | Intramuscular | “Eligible subjects will receive three IM injections with hVEGF26-104/RFASE on days 0 (primer), 14 and 28 (boosters).” NCT02237638 ↗ |